Abstract
Neonatal exposure to estrogenic and androgenic endocrine disruptors induces developmental abnormalities in the female reproductive system. To investigate whether neonatal exposure affects oogenesis in juvenile and pubertal ovary, Sprague-Dawley rat pups were given estrogen or various endocrine disruptors by a single injection on the day of birth at concentrations ranging between 2 mM to 40 mM, and sacrificed on day 21 (juvenile) or 50 (puberty). The ovaries were weighed and examined histologically at each stage. Further, 17 β-estradiol synthesis of oogenesis was analyzed using normal-phase high-performance liquid chromatography. Neonatal exposure to 17 β-estradiol, diethylstilbestrol and estrogen receptor inhibitors significantly reduced ovary weights, although estrogen receptor inhibitors were completely restored by 17 β-estradiol synthesis during puberty.
Keywords: Endocrine disruptor, neonatal exposure, ovary, oogenesis, 17 β-estradiol, estrogen receptor.
Drug Delivery Letters
Title:Study of Neonatal Exposure to Estrogenic and Androgenic Endocrine Disruptors by Normal-Phase HPLC
Volume: 2 Issue: 2
Author(s): Masahiro Kuwada, Rei Kawashima, Kazuo Nakamura, Hideyo Hasumi and Jun Maki
Affiliation:
Keywords: Endocrine disruptor, neonatal exposure, ovary, oogenesis, 17 β-estradiol, estrogen receptor.
Abstract: Neonatal exposure to estrogenic and androgenic endocrine disruptors induces developmental abnormalities in the female reproductive system. To investigate whether neonatal exposure affects oogenesis in juvenile and pubertal ovary, Sprague-Dawley rat pups were given estrogen or various endocrine disruptors by a single injection on the day of birth at concentrations ranging between 2 mM to 40 mM, and sacrificed on day 21 (juvenile) or 50 (puberty). The ovaries were weighed and examined histologically at each stage. Further, 17 β-estradiol synthesis of oogenesis was analyzed using normal-phase high-performance liquid chromatography. Neonatal exposure to 17 β-estradiol, diethylstilbestrol and estrogen receptor inhibitors significantly reduced ovary weights, although estrogen receptor inhibitors were completely restored by 17 β-estradiol synthesis during puberty.
Export Options
About this article
Cite this article as:
Kuwada Masahiro, Kawashima Rei, Nakamura Kazuo, Hasumi Hideyo and Maki Jun, Study of Neonatal Exposure to Estrogenic and Androgenic Endocrine Disruptors by Normal-Phase HPLC, Drug Delivery Letters 2012; 2 (2) . https://dx.doi.org/10.2174/2210304x11202020126
DOI https://dx.doi.org/10.2174/2210304x11202020126 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oral Beclomethasone: A Review of its Use in Inflammatory Bowel Disease
Mini-Reviews in Medicinal Chemistry Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia
Current Pharmaceutical Design New Frontiers in Alcoholism and Addiction Treatment
Recent Patents on CNS Drug Discovery (Discontinued) Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Recent Advances in the Understanding of Sepsis-Induced Alterations in the Neuroendocrine System
Endocrine, Metabolic & Immune Disorders - Drug Targets Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews Bioinformatics Analysis of Chicken miRNAs Associated with Monocyte to Macrophage Differentiation and Subsequent IFNγ Stimulated Activation
MicroRNA Prospects for Preventative Vaccines Against Prion Diseases
Protein & Peptide Letters Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Entrainment of the Human Circadian Clock to the Light-Dark Cycle and its Impact on Patients in the ICU and Nursing Home Settings
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research The Systemic Reaction During Inflammation: The Acute-Phase Proteins
Protein & Peptide Letters Selective Thyroid Hormone Receptor Modulators
Current Topics in Medicinal Chemistry Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology